This relationship is supported by a recent study by Bodas et al. that demonstrated that pan-HDAC inhibitors and an HDAC6 inhibitor reduced inflammation in CF mice challenged with lipopolysaccharide11. Here, HDAC6 is linked to cystic fibrosis.